Previous 10 | Next 10 |
Evoke Pharma finally received FDA approval for Gimoti, a nasal formulation of a generic GI drug, in June 2020 and launched the drug in October 2020. Post-approval, the stock price decreased as investors' dreams of the company being acquired faded, and the reality of a small company dr...
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common st...
Evoke Pharma (EVOK) has priced its public offering of 5M common shares at $2.50/share, for estimated gross proceeds of $12.5M.Underwriter's over-allotment is an additional 750K shares. Net proceeds will be used for working capital and general corporate purposes.Laidlaw & Company is acting...
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its...
Evoke Pharma (EVOK) dropped 5.1% in after-hours after it announced plans to offer and sell shares of its common stock in a firm commitment underwritten public offering; underwriters granted 45-day option to purchase an additional 15% of the shares.Actual size, terms of the offe...
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “fir...
Evoke Pharma shares jump ([[EVOK]] +14.4%) after it announces positive findings from a market research study for its diabetic gastroparesis treatment Gimoti.Evoke through its marketing partner, EVERSANA, conducted an ATU (Awareness, Trial, and Usage) study, a quantitative survey to measure ph...
Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutu...
SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced positive findings from...
SOLANA BEACH, Calif. and CHICAGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science indu...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK)...